Table 2.
Agreement of results between CSF-VDRL and CSF-TPPA or between CSF-TRUST and CSF-TPPA
| CSF-VDRL (n, %) |
CSF-TRUST (n, %) |
||||||
|---|---|---|---|---|---|---|---|
| Method |
+ | − | Subtotal | + | − | Subtotal | |
| CSF-TPPA (n, %) | + | 204 (24.8) | 232 (28.2) | 436 (52.9) | 182 (22.1) | 254 (30.8) | 436 (52.9) |
| − | 0 (0.0) | 388 (47.1) | 388 (47.1) | 0 (0.0) | 388 (47.1) | 388 (47.1) | |
| Subtotal | 204 (24.8) | 620 (75.2) | 824 | 182 (22.1) | 642 (77.9) | 824 | |
| p Value | <0.001* | <0.001† | |||||
*Comparison of reactive per cents for CSF-VDRL and CSF-TPPA.
†Comparison of reactive per cents for CSF-TRUST and CSF-TPPA.
CSF-TRUST, toluidine red unheated serum test on cerebrospinal fluids; CSF-VDRL, venereal disease research laboratory test on cerebrospinal fluids; CSF-TPPA, treponema palladium particle agglutination test on cerebrospinal fluids.